Skip to content
Parakho

Marksans Pharma Ltd

NSE MARKSANSBSE 524404marksanspharma.com

Q1 FY27, unaudited

Revenue
₹840.80 Cr
Profit after tax
₹159.41 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations840.80+35.61%2,950.94
Other income25.40+350.35%82.53
Total income866.20+38.45%3,033.47
Employee benefit expense114.29+16.17%420.93
Finance costs7.00+15.48%24.13
Depreciation & amortisation24.86+7.63%98.63
Total expenses659.63+20.14%2,472.92
Profit before tax206.57+169.68%560.56
Tax expense47.16+156.38%140.49
Profit after tax159.41+173.89%420.06
Total comprehensive income176.43+41.45%596.21
Earnings per share
Earnings per share, basic₹3.47₹9.22
Earnings per share, diluted₹3.47₹9.22

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Earnings call

Q4 FY26

Marksans Pharma reported Q4 FY26 operating revenue of Rs 856 crores, up 20.8% year-on-year, with EBITDA margin expanding to 22.8% and profit after tax rising 64.3% to Rs 149 crores. For the full year, revenue crossed Rs 3,000 crores for the first time, reaching Rs 2,951 crores, with EBITDA margin at 20.4% and a year-end cash balance of Rs 990 crores. Management discussed raw material cost inflation linked to petroleum-related inputs and geopolitical disruption, alongside growth across North America, U.K., and Australia markets and new market entries in Germany, Canada and Ireland.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 46 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 20 Aug 2026.